BMS 777607

Drug Profile

BMS 777607

Alternative Names: ASLAN-002; BMS-777607; BMS-797669

Latest Information Update: 07 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ASLAN Pharmaceuticals; Bristol-Myers Squibb; Huntsman Cancer Institute
  • Class Aminopyridines; Antineoplastics; Dihydropyridines; Pyridones; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer
  • Phase I Osteoporosis
  • No development reported Cancer; Head and neck cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 07 Mar 2017 No development reported - Phase-II for Head and neck cancer and Renal cell carcinoma (Late-stage disease, Metastatic disease) and Prostate cancer (Late-stage disease, Metastatic disease, Hormone refractory) in Australia (PO, Tablet and Suspension)
  • 20 Feb 2017 Phase-II development is ongoing for Gastric cancer (9212550; 9212551)
  • 20 Feb 2017 Phase-II clinical trials in Breast cancer (PO) before February 2017 (9212550; 9212551)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top